Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042934 | 0.89 | GRM5 (0.48) | GRM5FFAR1KCNH2ADRB3TSPO | |
| SCHEMBL5042334 | 0.89 | GRM5 (0.57) | GRM5FFAR1KCNH2PSEN1PSEN2 | |
| SCHEMBL5038503 | 0.82 | GRM5 (0.57) | GRM5FFAR1KCNH2PSEN1PSEN2 | |
| SCHEMBL2013401 | 0.82 | GRM5 (0.66) | GRM5FFAR1KCNH2 | |
| SCHEMBL5048046 | 0.81 | GRM5 (0.60) | GRM5FFAR1KCNH2PSEN1PSEN2 | |
| SCHEMBL2013751 | 0.80 | GRM5 (0.55) | GRM5FFAR1 | |
| SCHEMBL5042349 | 0.79 | GRM5 (0.55) | GRM5FFAR1KCNH2PSEN1PSEN2 | |
| SCHEMBL5038428 | 0.79 | GRM5 (0.55) | GRM5FFAR1KCNH2GABRPGABRD | |
| SCHEMBL2015726 | 0.79 | GRM5 (0.55) | GRM5FFAR1KCNH2GABRPGABRD | |
| SCHEMBL2008101 | 0.79 | GRM5 (0.65) | GRM5FFAR1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | claimed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | claimed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | claimed |
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7091222-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009878-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009878-A1 | Imidazole derivatives | GRIK5, GRM5, GRIK4 | GRM5 2/4885FFAR1 600/4885KCNH2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.